Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a shorter course of blood thinners be safer after a heart attack?

NCT ID NCT05491200

Disease control Sponsor: Research Maatschap Cardiologen Rotterdam Zuid Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study looks at people who have had a severe type of heart attack called STEMI. It compares a shorter course (about one month) of two blood thinners followed by just one drug (prasugrel) for a year, versus the standard one-year regimen of two blood thinners. The goal is to see if the shorter approach reduces bleeding complications while still preventing another heart attack or stroke. Some participants also receive either OCT-guided or angiography-guided stent placement to see which imaging method leads to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
prasugrel
What this could lead to
If successful, this could allow heart attack patients to take blood thinners for a shorter time, reducing bleeding risk while still preventing clots.
What could go wrong
This is a single trial with 1656 participants; results may not apply to all patients. Shorter therapy could increase the risk of heart attack or stroke in some individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 1,656 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Eligibility at index procedure All STEMI patients who are planned to be treated with PCI: ST segment elevation myocardial infarction Chest discomfort suggestive of cardiac ischemia ≥20 min at rest with 1 of the following ECG features: * ST segment elevation ≥2 contiguous ECG leads * new or presumably new left bundle branch block In patients with multivessel disease, treatment only of the culprit lesion / target vessel during primary PCI is recommended. Eligibility at 30-45 days * All patients who have provided informed consent * Compliance to DAPT with no regimen modifications (Non-adherence Academic Research Consortium 0) * No occurrence of significant event (such as MI, unplanned revascularisation, stent thrombosis, stroke, major vascular complication/bleeding BARC Types 3 or greater). * Successful revascularization: - Successful delivery and deployment of the Study device(s), with final residual stenosis of \<30% (visually) for all target lesions. * Complete revascularization performed when more than 1 significant lesion, during the index procedure or in staged procedure(s) occurring within 15 days from the index procedure. Physiologic assessment highly recommended for lesions with stenosis between 50% and 90%. Exclusion criteria * Patients on oral anticoagulation * Contraindication to P2Y12 inhibitors and/or to Cardioaspirin or to any of the excipients (hypersensitivity, history of any stroke or transient ischemic attack within the last 12 months, active bleeding or haemorrhagic diathesis, fibrin-specific fibrinolytic therapy less than 24 h before randomization, severe hepatic dysfunction (Child-Pugh C), history of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines, history of gastrointestinal perforation or acute gastrointestinal ulcers, severe cardiac failure (NYHA grade III or IV), combination with methotrexate at doses of 15 mg/week or more). * Patients who have received P2Y12 inhibitors other than Prasugrel in the ambulance (Ticagrelor or Clopidogrel loading dose) or are already on P2Y12 inhibitors, may be enrolled in the protocol, provided that the Prasugrel loading dose is administered at admission, according to current guidelines recommendations (see section 5.2.2). * Concomitant oral or i.v. therapy with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice \>1L/day), CYP3A substrates with narrow therapeutic indices (e.g., cyclosporine, quinidine), or strong CYP3A inducers (e.g., rifampin), - rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital * Platelet count \<100.000/μL at the time of screening * Anemia (hemoglobin \<10 g/dL) at the time of screening * Comorbidities associated with life expectancy \<1 year * Pregnancy, giving birth within the last 90 days, or lactation (see appendix III for women of childbearing potential) * PCI indication for stent thrombosis or previous history of definite stent thrombosis * Non-deferrable major surgery on DAPT after PCI * Cardiogenic shock * Out of hospital cardiac arrest (OHCA) unless survivors of ventricular arrythmia with prompt return of spontaneous circulation (ROSC) * Patients with severe renal impairment: creatinine clearance ≤30 ml/min/1.73 m2 (as calculated by MDRD formula for estimated GFR). * Patients participating in another interventional (device of drug trial) within the previous 12 months or patients to whom an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer. * No informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dual antiplatelet therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dual antiplatelet therapy ST elevated myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    27 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Delta

    RECRUITING

    Roeselare, Belgium

  • AZ St.Jan

    RECRUITING

    Bruges, Belgium

  • Albert Schweitzer ziekenhuis

    RECRUITING

    Dordrecht, Netherlands

  • Amphia Ziekenhuis

    RECRUITING

    Breda, 4818 CK, Netherlands

  • Asklepios Klinik Bad Oldesloe

    RECRUITING

    Bad Oldesloe, Germany

  • Catherina ziekenhuis

    RECRUITING

    Eindhoven, Netherlands

  • Centro Cardiologico Monzino IRCCS

    RECRUITING

    Milan, Italy

  • Charles University Hospital

    NOT_YET_RECRUITING

    Prague, Czechia

  • Erasmus Medical Center

    RECRUITING

    Rotterdam, Netherlands

  • FN BRNO

    RECRUITING

    Brno, Czechia

  • Haga hospital

    RECRUITING

    The Hague, Netherlands

  • Imelda Bonheiden

    RECRUITING

    Bonheiden, Belgium

  • Institute for CVD Dedinje

    RECRUITING

    Belgrade, Serbia

  • Institute for CVD Vojvodine

    RECRUITING

    Kamenitz, Serbia

  • Maasstadziekenhuis

    RECRUITING

    Rotterdam, Netherlands

  • Masaryk Hospital Usti nad Labem -

    RECRUITING

    Hradec Králové, Czechia

  • Ospedale Papa Giovanni XXIII

    RECRUITING

    Bergamo, Italy

  • RadboudUMC

    RECRUITING

    Nijmegen, Netherlands

  • Segeberger Kliniken

    RECRUITING

    Bad Segeberg, Germany

  • UZ Leuven

    RECRUITING

    Leuven, Belgium

  • University Federico II

    RECRUITING

    Naples, Italy

  • University Gemelli

    RECRUITING

    Roma, Italy

  • University San Martino

    RECRUITING

    Genova, Italy

  • University clinical center of Serbia

    RECRUITING

    Belgrade, Serbia

  • University hospital Dresden

    RECRUITING

    Dresden, Germany

  • University of Ferrara

    RECRUITING

    Ferrara, Italy

  • ZOL Genk

    RECRUITING

    Genk, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.